Telemark Asset Management LLC Sells 86,300 Shares of Biodesix, Inc. $BDSX

Telemark Asset Management LLC lowered its position in Biodesix, Inc. (NASDAQ:BDSX) by 20.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 327,824 shares of the company’s stock after selling 86,300 shares during the quarter. Telemark Asset Management LLC’s holdings in Biodesix were worth $2,229,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of Biodesix by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after purchasing an additional 2,235 shares during the period. Aberdeen Group plc bought a new position in shares of Biodesix in the fourth quarter worth $1,784,000. Oracle Investment Management Inc. bought a new position in shares of Biodesix in the third quarter worth $113,000. Millennium Management LLC bought a new position in shares of Biodesix in the third quarter worth $113,000. Finally, XTX Topco Ltd increased its holdings in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares during the period. Institutional investors own 20.96% of the company’s stock.

Biodesix Stock Down 6.3%

BDSX opened at $15.46 on Friday. The stock has a market cap of $160.17 million, a PE ratio of -3.81 and a beta of 0.59. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 5.09. Biodesix, Inc. has a 52 week low of $5.00 and a 52 week high of $20.21. The business’s fifty day simple moving average is $14.02 and its 200 day simple moving average is $11.69.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, May 4th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.32. The business had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $23.12 million. Biodesix had a negative return on equity of 2,101.40% and a negative net margin of 33.26%. As a group, research analysts expect that Biodesix, Inc. will post -2.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BDSX has been the topic of several research analyst reports. Weiss Ratings cut shares of Biodesix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 18th. William Blair raised shares of Biodesix from a “market perform” rating to an “outperform” rating in a report on Friday, February 27th. Finally, Canaccord Genuity Group upped their price target on shares of Biodesix from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Biodesix has an average rating of “Hold” and a consensus target price of $22.00.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.